Clinical Trials
Spheryx Awarded Phase II NIH SBIR Grant to Support...
Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for...
Clinical Trials
Viking Therapeutics Completes Enrollment in Phase 2 Study of...
Viking Therapeutics, Inc , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that enrollment has been...
Clinical Trials
Cannabics Pharmaceuticals Receives Positive Results In Drug Sensitivity Tests...
Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD...
Clinical Trials
Boston Biomedical Announces Unblinding of the Phase 3 Trial...
Boston Biomedical Inc, Â announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ...
Clinical Trials
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development...
OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for cancer immunotherapy. Submission of the Company's second Investigational New Drug...
Clinical Trials
goBalto and Informa Partner to Accelerate Site Selection for...
goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced its partnership with Citeline, part of Informa's Pharma Intelligence vertical, to integrate...
Clinical Trials
Astellas and Pfizer Announce Amendment to Clinical Research Protocol...
Astellas Pharma Inc and Pfizer Inc announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.